Theratechnologies

Theratechnologies, Inc. is a pharmaceutical company, which engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). The firm offers its product under the brand name of EGRIFTA, which is an approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. The company was founded on October 19, 1993 and is headquartered in Montréal, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MONTREAL, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today highlighted new data on the mechanism of effect of tesamorelin presented in an oral presentation given today by Lindsay T. Fourman, M.D., of the Metabolism Unit, Department of Medicine, Massachusetts General Hospital, at The Liver Meeting® 2020 of the American Association for the Study of Liver Diseases (AASLD).

Theratechnologies Announces Data From Oral Presentation at AASLD Showing How Tesamorelin Can Reduce Fibrosis and NASH

MONTREAL, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that an oral presentation including data on the mechanism of effect of tesamorelin in nonalcoholic fatty liver disease (NAFLD) will be given by Lindsay T Fourman, MD, of the Metabolism Unit, Department of Medicine, Massachusetts General Hospital, at The Liver Meeting® 2020 of the American Association for the Study of Liver Diseases (AASLD) to be held November 13-16, 2020.

Theratechnologies Announces that Data on the Mechanism of Effect of Tesamorelin in NAFLD will be Presented at The Liver Meeting® 2020

MONTREAL, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Jovan Antunovic, Senior Vice President and Chief Commercial Officer, is leaving the Company to assume a new position. His resignation will be effective November 13, 2020.

Theratechnologies Announces Departure of Chief Commercial Officer

MONTREAL, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that management will be presenting at the following upcoming virtual investor conferences.

Theratechnologies to Present at Upcoming Investor Conferences on October 29 and November 10, 2020

MONTREAL, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the appointment of Mr. Andrew Molson and Mr. Alain Trudeau as new independent members to its Board of Directors.

Theratechnologies Appoints Two New Board Members

MONTREAL, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,799,562, which is directed to the treatment of Nonalcoholic Steatohepatitis (NASH) and/or Nonalcoholic Fatty Liver Disease (NAFLD) in patients using tesamorelin.

Theratechnologies Confirms Issuance of U.S. Patent Covering the Use of Tesamorelin in the Treatment of Individuals Suffering From NAFLD/NASH

MONTREAL, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies) announced today that it will issue its financial results for the third quarter ended August 31, 2020 on Thursday, October 15, 2020.

Theratechnologies to Announce Financial Results for Third Quarter 2020

MONTREAL, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Dr. Christian Marsolais, Senior Vice President and Chief Medical Officer, will present at the H.C. Wainwright 4th Annual NASH Investor Conference on Monday, October 5, 2020 at 4:30 p.m. ET.

Theratechnologies to Present at the H.C. Wainwright 4th Annual NASH Investor Conference on October 5

MONTREAL, Sept.  21, 2020  (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced select preliminary financial results for the third quarter ended August 31, 2020.

Theratechnologies Announces Preliminary Third-Quarter  Fiscal 2020 Financial Results

Phase 3 protocol to be filed in Q4 2020; trial expected to begin early 2021

Theratechnologies to Develop Tesamorelin for the Treatment of NASH in the General Population

Theratechnologies Announces Launch of Trogarzo® in Germany

MONTREAL, July  30, 2020  (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced that Philippe Dubuc, the Senior Vice President and Chief Financial Officer of Theratechnologies, will present at the Canaccord Genuity Growth Conference on Wednesday, August 12, 2020 at 9:30 a.m. ET. 

Theratechnologies to Present at the Canaccord Genuity 40th Annual Growth Conference on August 12, 2020

Theratechnologies NASH Data And Other News: The Good, Bad And Ugly Of Biopharma

Sub-analysis of MGH    study helps better demonstrate how tesamorelin reduces liver fat

Theratechnologies Reports That Tesamorelin Improves Liver Health

Theratechnologies Inc. (THTX) CEO Paul Lévesque on Q2 2020 Results - Earnings Call Transcript

-Total product revenues of $17.2M, a 10% increase compared to Q2 2019 and 9% increase compared to Q1 2020-

Theratechnologies Announces Financial Results for the Second Quarter of Fiscal 2020

Theratechnologies Confirms Bioequivalence of New Tesamorelin Formulation

MONTREAL, July  06, 2020  (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that data presented at the 23rd International AIDS Conference virtual meeting, demonstrates that ibalizumab is active in vitro against group A and group B HIV-2.

Theratechnologies Announces Ibalizumab Inhibits HIV-2 In Vitro

Peptide-drug conjugates TH1902 and TH1904 show significant reduction in the formation of vasculogenic mimicry by targeting the sortilin receptor

New Data Show Theratechnologies’ SORT1+ Technology is Effective in Many Treatment-Resistant Cancers

Significant inhibition of vasculogenic mimicry observed with TH1902 and TH1904

Theratechnologies Unveils New Positive Data for Its Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Cancers

MONTREAL, April  16, 2020  (GLOBE NEWSWIRE) -- Theratechnologies Inc., or Theratechnologies (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, announced today that Paul Lévesque, the current President and Chief Executive Officer of Theratechnologies, was granted 487,421 stock options, or Options, to purchase an aggregate of 487,421 common shares of Theratechnologies under Nasdaq Listing Rule 5635(c)(4). The grant was made outside of Theratechnologies’ existing share option plan, or Plan, in connection with Mr. Lévesque’s previously-announced employment by Theratechnologies as its President and Chief Executive Officer. The Options were granted as an inducement material to Mr. Lévesque becoming the President and Chief Executive Officer of Theratechnologies on April 6, 2020.

Theratechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Theratechnologies Inc. (THTX) CEO Paul Lévesque on Q1 2020 Results - Earnings Call Transcript

New sub-analysis of MGH Study presented at CROI 2020 New sub-analysis of MGH Study presented at CROI 2020

Visceral Fat is a Predictor of Liver Fibrosis and Fibrosis Progression in People Living With HIV

Theratechnologies Inc. (THTX) CEO Luc Tanguay on Q4 2019 Results - Earnings Call Transcript

MONTREAL, Feb.  04, 2020  (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce the signing of long-term agreements with the Massachusetts General Hospital (MGH) and Dr. Steven Grinspoon towards the development of tesamorelin for the potential treatment  of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) in people living with HIV (Study).

News for Theratechnologies Stock (THTX)